Skip to main content
SpringerLink
Log in

Antikoagulation bei Vorhofflimmern

Risikostratifizierung als Basis des Therapieerfolges

  • Aktuelles
  • Published:
focus neurogeriatrie

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987;1:526–9

    Article  PubMed  CAS  Google Scholar 

  • Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257–354

    Article  PubMed  Google Scholar 

  • Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982;306:1018–22

    PubMed  CAS  Google Scholar 

  • Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118–50

    PubMed  CAS  Google Scholar 

  • Upshaw CB Jr. Hemodynamic changes after cardioversion of chronic atrial fibrillation. Arch Intern Med 1997;157:1070–6

    Article  PubMed  Google Scholar 

  • Allessie MA, Konings K, Kirchhof CJ, et al. Electrophysiologic mechanisms of perpetuation of atrial fibrillation. Am J Cardiol 1996;77:10A–23A

    Article  PubMed  CAS  Google Scholar 

  • Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987;317:669–74

    PubMed  CAS  Google Scholar 

  • Stroke Prevention in Atrial Fibrillation study. Final results. Circulation 1991;84:527–39

    Google Scholar 

  • Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154: 1449–57

    Google Scholar 

  • Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–67

    PubMed  Google Scholar 

  • Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864–70

    Article  PubMed  CAS  Google Scholar 

  • Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004;110: 2287–92

    Article  PubMed  CAS  Google Scholar 

  • Hellemons BS, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 1999;319:958–64

    PubMed  CAS  Google Scholar 

  • Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 2000;31:817–21

    PubMed  CAS  Google Scholar 

  • Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175–9

    Article  PubMed  CAS  Google Scholar 

  • Edvardsson N, Juul-Moller S, Omblus R, et al. Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. J Intern Med 2003;254:95–101

    Article  PubMed  CAS  Google Scholar 

  • Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006; 37:447–51

    Article  PubMed  CAS  Google Scholar 

  • Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342:1255–62

    Google Scholar 

  • Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343:687–91

  • Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998;158:1513–21

    Article  PubMed  CAS  Google Scholar 

  • Vemmos KN, Tsivgoulis G, Spengos K, et al. Primary prevention of arterial thromboembolism in the oldest old with atrial fibrillation – a randomized pilot trial comparing adjusted- dose and fixed low-dose coumadin with aspirin. Eur J Intern Med 2006;17:48–52

    Article  PubMed  CAS  Google Scholar 

  • Rash A, Downes T, Portner R, et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007;36:151–6

    Article  PubMed  Google Scholar 

  • Morocutti C, Amabile G, Fattapposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 1997;28:1015–21

    PubMed  CAS  Google Scholar 

  • Perez-Gomez F, Alegria E, Berjon J, et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004;44:1557–66

    Article  PubMed  CAS  Google Scholar 

  • Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903–12

    Article  PubMed  CAS  Google Scholar 

  • Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA): a randomised controlled trial. Lancet 2007;370:493–503

    Article  PubMed  CAS  Google Scholar 

  • Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633–8

  • Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with non-valvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003;41:1445–51

    Article  PubMed  CAS  Google Scholar 

  • Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691–8

    Article  PubMed  CAS  Google Scholar 

  • Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690–8

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. HerzKreislaufZentrum Klinik für Kardiologie, Universitätsspital Zürich, Switzerland

    Christian Binggeli

Authors
  1. Christian Binggeli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Binggeli, C. Antikoagulation bei Vorhofflimmern. focus neurogeriatrie 2, 12–16 (2008). https://doi.org/10.1007/s12151-008-0130-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12151-008-0130-x

Search

Navigation